Trovagene's PLK1 inhibitor PCM-075 significantly enhances efficacy of a FLT3 inhibitor
Trovagene announced positive data from a preclinical in-vivo study examining the combination of their PLK1 inhibitor, PCM-075, with a leading investigational FLT3 Inhibitor. This FLT3 mutant xenograft model shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition. August 16, 2017